Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 289 matching trials from the live ClinicalTrials.gov search.
Conditions
Fatty Liver
Interventions
Glucophage (Metformin), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Non-alcoholic Steatohepatitis
Interventions
Vonafexor, Placebo
Drug · Other
Lead sponsor
Enyo Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Lakewood Rch, Florida • Ocoee, Florida + 19 more
Completed Phase 1Phase 2 Interventional

Fatty Liver Disease in Obese Children

NCT02117700
Conditions
Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
Interventions
N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day, Placebo twice/day
Dietary Supplement · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Dose and Nonalcoholic Fatty Liver Disease

NCT00771108
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
exercise
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Interventions
Sodium Octanoate Breath Test
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Conditions
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions
Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
Behavioral
Lead sponsor
Grand Valley State University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wyoming, Michigan
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
MEDI0382 high dose, Placebo for MEDI0382 high dose, MEDI0382 low dose, Placebo for MEDI0382 low dose
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Tucson, Arizona • Canoga Park, California • Chula Vista, California + 19 more
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
35 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Culturelle (Lactobacillus rhamnosus strain GG), Placebo
Dietary Supplement · Other
Lead sponsor
Northwell Health
Other
Eligibility
5 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Conditions
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
80
States / cities
Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more
Conditions
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Cenicriviroc 150 mg, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
8
States / cities
La Jolla, California • San Francisco, California • Indianapolis, Indiana + 5 more
Conditions
Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018, Interleukin-17 MeSH Descriptor Data 2018
Interventions
Probiotic Formulation VSL#3
Biological
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Non Alcoholic Fatty Liver Disease, Obstructive Sleep Apnea
Interventions
CPAP (ResMed S9 autoset CPAP)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 2 Interventional

Digoxin In NASH (CODIN)

NCT06588699
Conditions
NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions
Digoxin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
LYS006, Tropifexor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Coronado, California • Los Angeles, California • Miami Lakes, Florida + 5 more
Conditions
Healthy, NAFLD
Interventions
ASC41, Itraconazole, Phenytoin
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, MASH
Interventions
ALN-CIDEB, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
22
States / cities
Tucson, Arizona • Pasadena, California • Rialto, California + 16 more